Global Interleukin Inhibitors Market

Interleukin Inhibitors Comprehensive Study by Type (IL-17, IL-23, IL-1, IL-5, IL-6, Others), Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others), Distribution Channels (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes) Players and Region - Global Market Outlook to 2030

Interleukin Inhibitors Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Interleukin Inhibitors
Interleukin inhibitors are immunosuppressive agents that inhibit the action of interleukins. It is used in various conditions including ankylosing, spondylitis, asthma, eczema, (psoriatic and rheumatoid), psoriasis, and systematic sclerosis, gout, arthritis. Interleukin inhibitors market has high growth prospects due to growing prevalence of chronic inflammatory diseases and proactive government initiatives. The major companies are adding more innovative techniques in Asia-Pacific countries as these countries are focused on fastest-growing verticals for the Healthcare industries.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketEurope
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Interleukin Inhibitors market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Regeneron Pharmaceuticals, Inc. (United States), Novartis AG (Switzerland), Valeant Pharmaceuticals, Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson. (United States), Genentech, Inc. (Roche) (United States), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Sanofi S.A. (France), AstraZeneca plc. (United Kingdom) and F. Hoffmann-La Roche Ltd. (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Interleukin Inhibitors market by Type (IL-17, IL-23, IL-1, IL-5, IL-6 and Others), Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD) and Others) and Region.



On the basis of geography, the market of Interleukin Inhibitors has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Distribution Channels, the sub-segment i.e. Hospital Pharmacies will boost the Interleukin Inhibitors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Demand from Asia-Pacific Regions and Value-Oriented Customers

Market Growth Drivers:
Growing Prevalence of Autoimmune Diseases and Increasing Adoption of Technology Advanced Biosimilar in Tumor Necrosis Factor (TNF) Inhibitors

Challenges:
Product Recall Hamper the Market Growth and Stiff Competition among Major Players

Restraints:
Side Effect Associated with Interleukin Inhibitors and High Cost Associated with Biological Therapy

Opportunities:
Consumer Preference towards Health Conscious Product and Economic Development and Improvement in Healthcare Expenditure

Market Leaders and their expansionary development strategies
In June 2023, Eli Lilly has acquired DICE Therapeutics. The acquisition designed to expand the buyer’s immunology pipeline with two clinical-stage programs based on oral interleukin-17 (IL-17) inhibitors.
In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2


Key Target Audience
Interleukin Inhibitors Manufacturer, Interleukin Inhibitors Supplier, End User of Different Segments of Interleukin Inhibitors, R&D Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others
By Application
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease (IBD)
  • Others
By Distribution Channels
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Clinics
  • Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Autoimmune Diseases
      • 3.2.2. Increasing Adoption of Technology Advanced Biosimilar in Tumor Necrosis Factor (TNF) Inhibitors
    • 3.3. Market Challenges
      • 3.3.1. Product Recall Hamper the Market Growth
      • 3.3.2. Stiff Competition among Major Players
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand from Asia-Pacific Regions
      • 3.4.2. Value-Oriented Customers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Interleukin Inhibitors, by Type, Application, Distribution Channels and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Interleukin Inhibitors (Value)
      • 5.2.1. Global Interleukin Inhibitors by: Type (Value)
        • 5.2.1.1. IL-17
        • 5.2.1.2. IL-23
        • 5.2.1.3. IL-1
        • 5.2.1.4. IL-5
        • 5.2.1.5. IL-6
        • 5.2.1.6. Others
      • 5.2.2. Global Interleukin Inhibitors by: Application (Value)
        • 5.2.2.1. Psoriasis
        • 5.2.2.2. Psoriatic Arthritis
        • 5.2.2.3. Rheumatoid Arthritis
        • 5.2.2.4. Asthma
        • 5.2.2.5. Inflammatory Bowel Disease (IBD)
        • 5.2.2.6. Others
      • 5.2.3. Global Interleukin Inhibitors by: Distribution Channels (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Online Pharmacies
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Clinics
        • 5.2.3.5. Research Institutes
      • 5.2.4. Global Interleukin Inhibitors Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Interleukin Inhibitors (Price)
      • 5.3.1. Global Interleukin Inhibitors by: Type (Price)
  • 6. Interleukin Inhibitors: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Valeant Pharmaceuticals, Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech, Inc. (Roche) (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc. (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Interleukin Inhibitors Sale, by Type, Application, Distribution Channels and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Interleukin Inhibitors (Value)
      • 7.2.1. Global Interleukin Inhibitors by: Type (Value)
        • 7.2.1.1. IL-17
        • 7.2.1.2. IL-23
        • 7.2.1.3. IL-1
        • 7.2.1.4. IL-5
        • 7.2.1.5. IL-6
        • 7.2.1.6. Others
      • 7.2.2. Global Interleukin Inhibitors by: Application (Value)
        • 7.2.2.1. Psoriasis
        • 7.2.2.2. Psoriatic Arthritis
        • 7.2.2.3. Rheumatoid Arthritis
        • 7.2.2.4. Asthma
        • 7.2.2.5. Inflammatory Bowel Disease (IBD)
        • 7.2.2.6. Others
      • 7.2.3. Global Interleukin Inhibitors by: Distribution Channels (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Online Pharmacies
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Clinics
        • 7.2.3.5. Research Institutes
      • 7.2.4. Global Interleukin Inhibitors Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Interleukin Inhibitors (Price)
      • 7.3.1. Global Interleukin Inhibitors by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Interleukin Inhibitors: by Type(USD Million)
  • Table 2. Interleukin Inhibitors IL-17 , by Region USD Million (2018-2023)
  • Table 3. Interleukin Inhibitors IL-23 , by Region USD Million (2018-2023)
  • Table 4. Interleukin Inhibitors IL-1 , by Region USD Million (2018-2023)
  • Table 5. Interleukin Inhibitors IL-5 , by Region USD Million (2018-2023)
  • Table 6. Interleukin Inhibitors IL-6 , by Region USD Million (2018-2023)
  • Table 7. Interleukin Inhibitors Others , by Region USD Million (2018-2023)
  • Table 8. Interleukin Inhibitors: by Application(USD Million)
  • Table 9. Interleukin Inhibitors Psoriasis , by Region USD Million (2018-2023)
  • Table 10. Interleukin Inhibitors Psoriatic Arthritis , by Region USD Million (2018-2023)
  • Table 11. Interleukin Inhibitors Rheumatoid Arthritis , by Region USD Million (2018-2023)
  • Table 12. Interleukin Inhibitors Asthma , by Region USD Million (2018-2023)
  • Table 13. Interleukin Inhibitors Inflammatory Bowel Disease (IBD) , by Region USD Million (2018-2023)
  • Table 14. Interleukin Inhibitors Others , by Region USD Million (2018-2023)
  • Table 15. Interleukin Inhibitors: by Distribution Channels(USD Million)
  • Table 16. Interleukin Inhibitors Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 17. Interleukin Inhibitors Online Pharmacies , by Region USD Million (2018-2023)
  • Table 18. Interleukin Inhibitors Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 19. Interleukin Inhibitors Clinics , by Region USD Million (2018-2023)
  • Table 20. Interleukin Inhibitors Research Institutes , by Region USD Million (2018-2023)
  • Table 21. South America Interleukin Inhibitors, by Country USD Million (2018-2023)
  • Table 22. South America Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 23. South America Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 24. South America Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 25. Brazil Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 26. Brazil Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 27. Brazil Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 28. Argentina Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 29. Argentina Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 30. Argentina Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 31. Rest of South America Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 34. Asia Pacific Interleukin Inhibitors, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 38. China Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 39. China Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 40. China Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 41. Japan Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 42. Japan Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 43. Japan Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 44. India Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 45. India Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 46. India Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 47. South Korea Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 48. South Korea Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 49. South Korea Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 50. Taiwan Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 51. Taiwan Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 52. Taiwan Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 53. Australia Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 54. Australia Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 55. Australia Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 59. Europe Interleukin Inhibitors, by Country USD Million (2018-2023)
  • Table 60. Europe Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 61. Europe Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 62. Europe Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 63. Germany Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 64. Germany Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 65. Germany Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 66. France Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 67. France Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 68. France Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 69. Italy Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 70. Italy Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 71. Italy Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 72. United Kingdom Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 73. United Kingdom Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 74. United Kingdom Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 75. Netherlands Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 76. Netherlands Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 77. Netherlands Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 78. Rest of Europe Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 79. Rest of Europe Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 80. Rest of Europe Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 81. MEA Interleukin Inhibitors, by Country USD Million (2018-2023)
  • Table 82. MEA Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 83. MEA Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 84. MEA Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 85. Middle East Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 86. Middle East Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 87. Middle East Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 88. Africa Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 89. Africa Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 90. Africa Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 91. North America Interleukin Inhibitors, by Country USD Million (2018-2023)
  • Table 92. North America Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 93. North America Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 94. North America Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 95. United States Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 96. United States Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 97. United States Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 98. Canada Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 99. Canada Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 100. Canada Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 101. Mexico Interleukin Inhibitors, by Type USD Million (2018-2023)
  • Table 102. Mexico Interleukin Inhibitors, by Application USD Million (2018-2023)
  • Table 103. Mexico Interleukin Inhibitors, by Distribution Channels USD Million (2018-2023)
  • Table 104. Interleukin Inhibitors: by Type(USD/Units)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Interleukin Inhibitors: by Type(USD Million)
  • Table 117. Interleukin Inhibitors IL-17 , by Region USD Million (2025-2030)
  • Table 118. Interleukin Inhibitors IL-23 , by Region USD Million (2025-2030)
  • Table 119. Interleukin Inhibitors IL-1 , by Region USD Million (2025-2030)
  • Table 120. Interleukin Inhibitors IL-5 , by Region USD Million (2025-2030)
  • Table 121. Interleukin Inhibitors IL-6 , by Region USD Million (2025-2030)
  • Table 122. Interleukin Inhibitors Others , by Region USD Million (2025-2030)
  • Table 123. Interleukin Inhibitors: by Application(USD Million)
  • Table 124. Interleukin Inhibitors Psoriasis , by Region USD Million (2025-2030)
  • Table 125. Interleukin Inhibitors Psoriatic Arthritis , by Region USD Million (2025-2030)
  • Table 126. Interleukin Inhibitors Rheumatoid Arthritis , by Region USD Million (2025-2030)
  • Table 127. Interleukin Inhibitors Asthma , by Region USD Million (2025-2030)
  • Table 128. Interleukin Inhibitors Inflammatory Bowel Disease (IBD) , by Region USD Million (2025-2030)
  • Table 129. Interleukin Inhibitors Others , by Region USD Million (2025-2030)
  • Table 130. Interleukin Inhibitors: by Distribution Channels(USD Million)
  • Table 131. Interleukin Inhibitors Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 132. Interleukin Inhibitors Online Pharmacies , by Region USD Million (2025-2030)
  • Table 133. Interleukin Inhibitors Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 134. Interleukin Inhibitors Clinics , by Region USD Million (2025-2030)
  • Table 135. Interleukin Inhibitors Research Institutes , by Region USD Million (2025-2030)
  • Table 136. South America Interleukin Inhibitors, by Country USD Million (2025-2030)
  • Table 137. South America Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 138. South America Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 139. South America Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 140. Brazil Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 141. Brazil Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 142. Brazil Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 143. Argentina Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 144. Argentina Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 145. Argentina Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 146. Rest of South America Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 147. Rest of South America Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 148. Rest of South America Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 149. Asia Pacific Interleukin Inhibitors, by Country USD Million (2025-2030)
  • Table 150. Asia Pacific Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 151. Asia Pacific Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 152. Asia Pacific Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 153. China Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 154. China Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 155. China Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 156. Japan Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 157. Japan Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 158. Japan Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 159. India Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 160. India Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 161. India Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 162. South Korea Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 163. South Korea Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 164. South Korea Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 165. Taiwan Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 166. Taiwan Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 167. Taiwan Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 168. Australia Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 169. Australia Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 170. Australia Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 172. Rest of Asia-Pacific Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 173. Rest of Asia-Pacific Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 174. Europe Interleukin Inhibitors, by Country USD Million (2025-2030)
  • Table 175. Europe Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 176. Europe Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 177. Europe Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 178. Germany Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 179. Germany Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 180. Germany Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 181. France Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 182. France Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 183. France Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 184. Italy Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 185. Italy Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 186. Italy Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 187. United Kingdom Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 188. United Kingdom Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 189. United Kingdom Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 190. Netherlands Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 191. Netherlands Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 192. Netherlands Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 193. Rest of Europe Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 194. Rest of Europe Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 195. Rest of Europe Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 196. MEA Interleukin Inhibitors, by Country USD Million (2025-2030)
  • Table 197. MEA Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 198. MEA Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 199. MEA Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 200. Middle East Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 201. Middle East Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 202. Middle East Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 203. Africa Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 204. Africa Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 205. Africa Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 206. North America Interleukin Inhibitors, by Country USD Million (2025-2030)
  • Table 207. North America Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 208. North America Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 209. North America Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 210. United States Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 211. United States Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 212. United States Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 213. Canada Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 214. Canada Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 215. Canada Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 216. Mexico Interleukin Inhibitors, by Type USD Million (2025-2030)
  • Table 217. Mexico Interleukin Inhibitors, by Application USD Million (2025-2030)
  • Table 218. Mexico Interleukin Inhibitors, by Distribution Channels USD Million (2025-2030)
  • Table 219. Interleukin Inhibitors: by Type(USD/Units)
  • Table 220. Research Programs/Design for This Report
  • Table 221. Key Data Information from Secondary Sources
  • Table 222. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Interleukin Inhibitors: by Type USD Million (2018-2023)
  • Figure 5. Global Interleukin Inhibitors: by Application USD Million (2018-2023)
  • Figure 6. Global Interleukin Inhibitors: by Distribution Channels USD Million (2018-2023)
  • Figure 7. South America Interleukin Inhibitors Share (%), by Country
  • Figure 8. Asia Pacific Interleukin Inhibitors Share (%), by Country
  • Figure 9. Europe Interleukin Inhibitors Share (%), by Country
  • Figure 10. MEA Interleukin Inhibitors Share (%), by Country
  • Figure 11. North America Interleukin Inhibitors Share (%), by Country
  • Figure 12. Global Interleukin Inhibitors: by Type USD/Units (2018-2023)
  • Figure 13. Global Interleukin Inhibitors share by Players 2023 (%)
  • Figure 14. Global Interleukin Inhibitors share by Players (Top 3) 2023(%)
  • Figure 15. Global Interleukin Inhibitors share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. Valeant Pharmaceuticals, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Valeant Pharmaceuticals, Inc. (Canada) Revenue: by Geography 2023
  • Figure 23. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 25. Johnson & Johnson. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson. (United States) Revenue: by Geography 2023
  • Figure 27. Genentech, Inc. (Roche) (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genentech, Inc. (Roche) (United States) Revenue: by Geography 2023
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 35. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 37. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 39. Global Interleukin Inhibitors: by Type USD Million (2025-2030)
  • Figure 40. Global Interleukin Inhibitors: by Application USD Million (2025-2030)
  • Figure 41. Global Interleukin Inhibitors: by Distribution Channels USD Million (2025-2030)
  • Figure 42. South America Interleukin Inhibitors Share (%), by Country
  • Figure 43. Asia Pacific Interleukin Inhibitors Share (%), by Country
  • Figure 44. Europe Interleukin Inhibitors Share (%), by Country
  • Figure 45. MEA Interleukin Inhibitors Share (%), by Country
  • Figure 46. North America Interleukin Inhibitors Share (%), by Country
  • Figure 47. Global Interleukin Inhibitors: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Regeneron Pharmaceuticals, Inc. (United States)
  • Novartis AG (Switzerland)
  • Valeant Pharmaceuticals, Inc. (Canada)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Johnson & Johnson. (United States)
  • Genentech, Inc. (Roche) (United States)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Sanofi S.A. (France)
  • AstraZeneca plc. (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
Select User Access Type

Key Highlights of Report


Mar 2024 218 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Interleukin Inhibitors Market Quantitative research analysis
Global Interleukin Inhibitors Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Regeneron Pharmaceuticals, Inc. (United States), Novartis AG (Switzerland), Valeant Pharmaceuticals, Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson. (United States), Genentech, Inc. (Roche) (United States), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Sanofi S.A. (France), AstraZeneca plc. (United Kingdom) and F. Hoffmann-La Roche Ltd. (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Demand from Asia-Pacific Regions " is seen as one of major influencing trends for Interleukin Inhibitors Market during projected period 2023-2030.
The Interleukin Inhibitors market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Interleukin Inhibitors Market Report?

Have a Query? Click Here

Other Related Reports

Orthodontic Retainer Comprehensive Study by Type (Hawley retainer, Essix Retainer, Permanent Bonded Retainer), End users (Adult, Teen, Kids), Material type (Metal, Ceramic, Polymer Material, Others) ...
$ 3500
Breast Augmentation Implant Comprehensive Study by Type (Saline solution, Silicone gel, Composite filler), Application (Cosmetic Surgery, Reconstructive Surgery), Category (Saline breast implants, St...
$ 3750
Sample Evaporator Comprehensive Study by Type (Solvent, Gas, Solid, Powder, Others), Application (Biological, Medicine, Chemical, Food), Distribution Channel (Online, Offline) Players and Region - Gl...
$ 3500
Medical Diagnostic Imaging Devices Comprehensive Study by Type (Computed Tomography (CT), Computerized Axial Tomography (CAT), Computerized tomography Angiography (CTA), Magnetic Resonance Imaging (M...
$ 3750
Intracranial Pressure ICP monitoring Comprehensive Study by Application (Traumatic Brain Injury, Subarachnoid Hemorrhage, Meningitis, Intracerebral Hemorrhage, Others), End Users (Hospitals & Clinics...
$ 3750
Osteoarthritis Therapeutic Comprehensive Study by Drug (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids), Route of Administration (Parenteral, Topical,...
$ 3750